ILDONG HOLDINGS CO.,LTD
Financials
Valuation Metrics
ILDONG HOLDINGS CO.,LTD's Market Cap is ₩696B. At end of 2025 it was ₩1534B. Ranked #1548 of 2,421 in KR market (top 64%), #639 of 781 on KOSPI (top 82%), #171 of 231 in Pharmaceuticals, Biotechnology & Life Sciences (top 74%) by Market Cap.
Investment Metrics(as of 2026-09-18)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 69.59B KRW | KR#1,548/2,421 Sec#171/231 |
| Revenue | 595.15B KRW | KR#562/2,421 Sec#26/231 |
| Net Income | 43.94B KRW | KR#459/2,421 Sec#28/231 |
| Total Assets | 802.86B KRW | KR#549/2,421 Sec#30/231 |
| Net Assets | 345.58B KRW | KR#662/2,421 Sec#42/231 |
| Employees | 84 | KR#1,779/2,421 Sec#145/231 |
| Value | ||
| P/E | 1.58x | KR#44/2,421 Sec#2/231 |
| P/B | 0.20x | KR#121/2,421 Sec#4/231 |
| P/S | 0.12x | KR#177/2,421 Sec#1/231 |
| EV/EBITDA | 8.64x | KR#530/2,421 Sec#23/231 |
| FCF Yield | 18.44% | KR#343/2,421 Sec#6/231 |
| Profitability | ||
| ROE | 12.72% | KR#429/2,421 Sec#30/231 |
| ROA | 5.47% | KR#682/2,421 Sec#57/231 |
| Op. Margin | 3.97% | KR#1,094/2,421 Sec#77/231 |
| Revenue Growth | -5.76% | KR#1,805/2,421 Sec#171/231 |
| Earnings Growth | -34.80% | KR#1,001/2,421 Sec#65/231 |
| Financial Health | ||
| Debt Ratio | 132.32% | KR#1,812/2,421 Sec#202/231 |
| Total Debt | 211.25B KRW | KR#499/2,421 Sec#24/231 |
| FCF | 12.83B KRW | KR#644/2,421 Sec#36/231 |
| Cash | 76.61B KRW | KR#571/2,421 Sec#28/231 |
| Current Ratio | 0.81x | KR#1,930/2,421 Sec#188/231 |
| Net Debt/EBITDA | 5.70x | KR#1,070/2,421 Sec#80/231 |
| Dividend | ||
| Div. Yield | 1.66% | KR#957/2,421 Sec#51/231 |
| Div. Growth | -94.67% | KR—/2,421 Sec—/231 |
| Performance | ||
| 1Y Return | -36.46% | KR#1,747/2,421 Sec#143/231 |
| 1M Return | -1.79% | KR#1,455/2,421 Sec#112/231 |
| From 52W High | -64.88% | KR#2,028/2,421 Sec#164/231 |
| 1Y MDD | -64.20% | KR#1,711/2,421 Sec#143/231 |
| Trading | ||
| Volume | 6,055 shares | KR#2,083/2,421 Sec#200/231 |
| Trading Value | 36.4M KRW | KR#1,947/2,421 Sec#198/231 |
| Foreign Own. | 2.50% | KR#1,459/2,421 Sec#138/231 |
| Per Share | ||
| EPS | 3,808 KRW | KR#282/2,421 Sec#18/231 |
| BPS | 29,945 KRW | KR#378/2,421 Sec#27/231 |
Company Info
Established in 1941, this company transitioned to a holding company structure in 2016, with Ildong Pharmaceutical and UNIQPLAN as its main subsidiaries. Its subsidiaries engage in diverse businesses such as pharmaceutical manufacturing and sales, advertising agency services, and software development, generating profits through investments and other activities. The company is strengthening its competitiveness by establishing a fast and professional decision-making system and pursuing the dispersion of management risks by concentrating corporate capabilities. Ildong Holdings was founded in 1941 and is headquartered in Seocho-gu, Seoul.